NBY
NovaBay Pharmaceuticals, Inc.
NYSE MKT
People also watch:PIPIMUCOPXACYCCNBS
2.34-0.01 (-0.32%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close2.35
Open2.28
Bid2.31 x 100
Ask2.34 x 200
52wk Range1.75 - 15.00
Day's Range2.28 - 2.34
Volume15,891
Avg Vol (3m)42,109
As of 3:59 PM EDT. Market closed.
  • NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q1, 2016 By the Numbers
    Capital Cube2 months ago

    NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q1, 2016 By the Numbers

    Click here to see latest analysisNovaBay Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of NovaBay Pharmaceuticals, Inc. – Cempra, Inc., Oragenics, Inc., Tetraphase Pharmaceuticals, Inc., Johnson & Johnson and SIGA Technologies Inc (CEMP-US, OGEN-US, TTPH-US, JNJ-US and SIGA-US) that have also reported […] (Read more...) The post NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q1, 2016 By the Numbers appeared first on CapitalCube.

  • Benzinga3 months ago

    NovaBay Says Its Avenova Cuts Bacteria On Ocular Skin Surface By Over 90%

    NovaBay Pharmaceuticals, Inc. (NYSE: NBY ) revealed the presentation of clinical data demonstrating that its Avenova reduced the bacterial load on the ocular skin surface by over 90 percent in 20 minutes ...